Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681028 · ClinicalTrials.gov registry record · Phase 1
Feasibility of Individualized Therapy for Recurrent Glioblastoma
A Phase 1 study of Recurrent Glioblastoma, sponsored by Jennifer Clarke.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03681028 is a Phase 1 study of Recurrent Glioblastoma that has completed, run by Jennifer Clarke. The registered enrollment target is 30 participants, below the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03681028, a Phase 1 study of Recurrent Glioblastoma, has completed, sponsored by Jennifer Clarke.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study will test the ability and likelihood of successfully implementing individualized combination treatment recommendations for adult patients with surgically-resectable recurrent glioblastoma in a timely fashion. Collected tumor tissue and blood will be examined using a new diagnostic testing called University of California, San Francisco (UCSF) 500 Cancer Gene Panel which is done at the UCSF Clinical Cancer Genomics Laboratory. The UCSF 500 Cancer Gene Panel will help identify genetic changes in the DNA of a patient's cancer, which helps oncologists improve treatment by identifying targeted therapies.
Conditions Studied
Interventions
- DRUG Individualized therapy
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-12-19 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03681028
The ClinicalTrials.gov registry entry for NCT03681028 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (56% lower). The listed sponsor is Jennifer Clarke, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Individualized therapy is the first listed.
NCT03681028 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03681028 about?
NCT03681028 is a clinical study titled "Feasibility of Individualized Therapy for Recurrent Glioblastoma". The current study will test the ability and likelihood of successfully implementing individualized combination treatment recommendations for adult patients with surgically-resectable recurrent glioblastoma in a timely fashion. Collected tumor tissue and blood will be examined using a new diagnostic ...
What is the current status of trial NCT03681028?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-12-19. Estimated completion is 2024-12-31.
What conditions does trial NCT03681028 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma.
What interventions are being tested in trial NCT03681028?
The interventions under investigation include: Individualized therapy (DRUG).
Who is sponsoring clinical trial NCT03681028?
This trial is sponsored by Jennifer Clarke, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03681028 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
RECRUITING · Phase 1
-
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
RECRUITING · Phase 1
-
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
RECRUITING · Phase 1
-
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.